{"protocolSection": {"identificationModule": {"nctId": "NCT00697801", "orgStudyIdInfo": {"id": "MAP0010-CL-P201"}, "organization": {"fullName": "Allergan", "class": "INDUSTRY"}, "briefTitle": "Study of MAP0010 in Asthmatic Children and Adolescents", "officialTitle": "A Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group, Phase 2 Study Investigating the Efficacy, Tolerability and Pharmacokinetics of MAP0010 in Asthmatic Children and Adolescents Over 6 Weeks"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-07"}, "primaryCompletionDateStruct": {"date": "2006-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2006-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-12", "studyFirstSubmitQcDate": "2008-06-13", "studyFirstPostDateStruct": {"date": "2008-06-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-08-19", "resultsFirstSubmitQcDate": "2013-08-19", "resultsFirstPostDateStruct": {"date": "2013-10-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-09", "lastUpdatePostDateStruct": {"date": "2014-01-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Allergan", "class": "INDUSTRY"}, "collaborators": [{"name": "MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 208, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MAP0010 low dose", "type": "EXPERIMENTAL", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks", "interventionNames": ["Drug: MAP0010 low dose"]}, {"label": "MAP0010 high dose", "type": "EXPERIMENTAL", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks", "interventionNames": ["Drug: MAP0010 high dose"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo delivered by nebulization twice daily for 6 weeks", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "MAP0010 low dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks", "armGroupLabels": ["MAP0010 low dose"]}, {"type": "DRUG", "name": "MAP0010 high dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks", "armGroupLabels": ["MAP0010 high dose"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo delivered by nebulization twice daily for 6 weeks", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Daytime Composite Symptom Score", "description": "The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nDaily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.", "timeFrame": "baseline, week 6"}, {"measure": "Change From Baseline in Nighttime Composite Symptom Score", "description": "The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nNightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.", "timeFrame": "baseline, week 6"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FEV1% Predicted", "description": "The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).", "timeFrame": "baseline, week 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female asthmatic children/adolescents\n* 1 to 18 years of age\n* FEV1 greater than or equal to 50% predicted normal (where obtainable)\n* Stable but symptomatic\n* Diagnosis of asthma (per NIH criteria) at least 3 months before screening OR documented exacerbation or worsening of asthma or symptoms suggestive of asthma including nocturnal asthma, within 6 months of screening OR documented SAB use more than or at least once for symptom relief during the 4 days of run in with a total symptom score greater than or equal to 1 OR greater than or equal to 1 night disturbed due to asthma symptoms in previous month.\n\nExclusion Criteria:\n\n* Any other significant childhood illness.\n* Participated in any investigational clinical trial within the 30 days prior to screening.\n* Use of any corticosteroid within 2 weeks of screening.\n* Use of oral corticosteroid within 30 days of screening or prolonged use of oral corticosteroids within 12 weeks of screening.\n* Use of inhaled long acting bronchodilators.\n* Presumptive or documented history of upper or lower respiratory infection within 2 weeks before screening.\n* Any history of acute or severe asthma attack requiring ICU admission or ventilatory support.\n* History suggestive (or diagnosis) of other concomitant lung disease.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "1 Year", "maximumAge": "18 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks"}, {"id": "FG001", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks"}, {"id": "FG002", "title": "Placebo", "description": "Placebo delivered by nebulization twice daily for 6 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "70"}, {"groupId": "FG002", "numSubjects": "69"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "57"}, {"groupId": "FG001", "numSubjects": "58"}, {"groupId": "FG002", "numSubjects": "45"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "24"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The baseline characteristics are summarized on the Intent-to-treat population (those patients with at least 1 on treatment efficacy evaluation including 1 electronic diary entry).", "groups": [{"id": "BG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks"}, {"id": "BG001", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks"}, {"id": "BG002", "title": "Placebo", "description": "Placebo delivered by nebulization twice daily for 6 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "65"}, {"groupId": "BG003", "value": "198"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.2", "spread": "4.76"}, {"groupId": "BG001", "value": "10.5", "spread": "4.75"}, {"groupId": "BG002", "value": "10.2", "spread": "4.52"}, {"groupId": "BG003", "value": "10.3", "spread": "4.68"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "72"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "45"}, {"groupId": "BG003", "value": "126"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Daytime Composite Symptom Score", "description": "The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nDaily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "baseline, week 6", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks"}, {"id": "OG001", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo delivered by nebulization twice daily for 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "65"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "spread": "1.90"}, {"groupId": "OG001", "value": "2.8", "spread": "1.75"}, {"groupId": "OG002", "value": "2.6", "spread": "1.59"}]}]}, {"title": "Change from Baseline at week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "1.80"}, {"groupId": "OG001", "value": "-1.4", "spread": "1.48"}, {"groupId": "OG002", "value": "-0.6", "spread": "1.63"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Nighttime Composite Symptom Score", "description": "The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.\n\nThe individual symptoms were scored using a four point scale:\n\n0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms\n\nNightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "baseline, week 6", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks"}, {"id": "OG001", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo delivered by nebulization twice daily for 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "65"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "1.96"}, {"groupId": "OG001", "value": "2.4", "spread": "1.75"}, {"groupId": "OG002", "value": "2.4", "spread": "1.49"}]}]}, {"title": "Change from Baseline at week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "2.00"}, {"groupId": "OG001", "value": "-1.2", "spread": "1.42"}, {"groupId": "OG002", "value": "-0.4", "spread": "1.60"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in FEV1% Predicted", "description": "The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of predicted FEV1", "timeFrame": "baseline, week 6", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks"}, {"id": "OG001", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo delivered by nebulization twice daily for 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.8", "spread": "11.45"}, {"groupId": "OG001", "value": "73.8", "spread": "13.10"}, {"groupId": "OG002", "value": "65.9", "spread": "7.22"}]}]}, {"title": "Change from Baseline at 6 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.3", "spread": "9.87"}, {"groupId": "OG001", "value": "6.3", "spread": "7.73"}, {"groupId": "OG002", "value": "5.9", "spread": "8.73"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All patients who received any study drug and who had at least one post safety evaluation were included in the adverse event analysis.", "eventGroups": [{"id": "EG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 69, "otherNumAffected": 21, "otherNumAtRisk": 69}, {"id": "EG001", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 67, "otherNumAffected": 10, "otherNumAtRisk": 67}, {"id": "EG002", "title": "Placebo", "description": "Placebo delivered by nebulization twice daily for 6 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 69, "otherNumAffected": 20, "otherNumAtRisk": 69}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 67}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 69}]}, {"term": "Upper Respiratory Infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 67}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 69}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 69}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 67}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 69}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."}, "pointOfContact": {"title": "VP, Scientific Affairs", "organization": "MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan", "email": "dkellerman@mappharma.com", "phone": "650-386-3100"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}